Main text:
To the editor:
Systemic autoinflammatory
syndromes are rare monogenic disorders generally characterized by
recurrent episodes of fever accompanied by systemic inflammation without
an identifiable infectious or autoimmune cause (1).
The nucleotide-binding leucine-rich repeat-containing receptor 12
(NLRP12 ) gene is a member of the NLRP family. Through its
activation by foreign microbial proteins and damaged intracellular
components, NLRP12 plays a role in steady-state regulation of
innate immunity (2). NLRP12 heterozygous mutations are known to
cause Familial Cold Autoinflammatory Syndrome 2 (FCAS2), inherited in an
autosomal dominant fashion (3). It is usually induced by cold, and in
most cases, it has an early onset in childhood. The most common clinical
presentation is fever associated to multisystemic symptoms such as
polyarthralgia/arthritis, abdominal pain and diarrhea, rash,
lymphadenopathy/splenomegaly, headache, neurosensory deafness and
aphthous stomatitis (3). To date approximately 33 cases ofNLRP12 -associated autoinflammatory syndromes in children have
been reported and 21 different NLRP12 disease causing variants
have been associated to FCAS2, including 16 missense, 3 frameshift and 2
nonsense (3). In many cases of FCAS2, the NLRP12 variant was
present in non-affected first-degree relatives, indicating incomplete
penetrance of the disease and pointing the possibility of the
contribution of other genetic and environmental factors for the clinical
expression of the disease (3).
With the aim of expanding the clinical spectrum of NLRP12- related
autoinflammatory disorders, the authors describe the case of an
adolescent with a novel NLRP12 variant presenting with recurrent
febrile episodes, cold urticaria and hemophagocytic lymphohistiocytosis,
never reported in patients harbouring NLRP12 mutations.
A 14-year-old boy, born of nonconsanguineous parents, presented to the
emergency department with a three-week history of a pruritic,
generalized maculo-papular rash with centrifugal distribution (Figure
1). In the 2 days previous to his first hospital observation, he had
sore throat and high fever (maximum 39,5ºC with 3 hours intervals). On
the day of observation, he additionally had bilateral conjunctival
hyperemia, headache and myalgia of the upper thighs. He had a previous
medical history of growth hormone deficiency treated with growth hormone
substitution therapy; myositis of unknown origin at 8 years of age, an
episode of cold urticaria at 10 years of age treated with
methylprednisolone and three previous episodes of fever of unknown
origin. Regarding his family history, his father had a previous
diagnosis of cold urticaria and migraine.
At hospital admission laboratory investigation revealed an elevated
C-reactive protein (CRP) of 113.4 mg/L, D-Dimer of 4986 ng/ml, lactate
dehydrogenase (LDH) of 432 UI/ml, together with neutrophilia and
lymphopenia (leucocytes 14.410/ul, neutrophils 13440/ul, lymphocytes
630/ul). He was admitted and started intravenous ceftriaxone. On the
following day he developed dyspnea and hypoxemia. The chest X-ray showed
a diffuse “cotton-like” infiltrate, confirmed by thoracic CT-scan that
also revealed a bilateral pleural effusion. Invasive streptococcal
disease was suspected, and he was started on intravenous penicillin,
clindamycin and two consecutive administrations of intravenous
immunoglobulin (1gr/kg/day). Although all the laboratory investigations
for infectious diseases were negative (Table 1), he had a progressive
clinical improvement after this treatment was started, with his fever
settling, partial resolution of the skin rash and a significant and
progressive improvement of the inflammatory parameters. On day 15 of
admission, he presented again with high fever, confluent skin rash and
hepatosplenomegaly. Laboratory evaluation showed haemoglobin 7,7 g/dL,
leucocytes 4300/ul, increased liver enzymes (AST 465 UI/L, ALT 136 UI/L,
GGT 232 UI/L), elevated inflammatory parameters (CRP 220 mg/L; serum
amyloid A 1200 mg/L); elevated ferritin (50252 ng/ml), soluble CD25
(5227 pg/mL) and fasting triglycerides (423 mg/dL), which together with
splenomegaly fulfilled 5/8 criteria for hemophagocytic
lymphohistiocytosis (HLH). (4) NK cytotoxicity and degranulation assays
were both normal. He was started on daily methylprednisolone pulses (30
mg/kg) for five days, followed by oral prednisolone (2 mg/kg/day for 2
weeks), with resolution of the fever episodes and a progressive
improvement of the inflammatory markers. When clinically stable, he was
discharged with a tapering steroid scheme. Four weeks after stopping
steroids, following exposure to cold water, he again developed fever,
elevated inflammatory markers, and a maculopapular rash with target
lesions (figure 1). The symptoms resolved with prednisolone but relapsed
five days after its interruption. He was then started on long-term
treatment with the recombinant interleukin-1 receptor antagonist,
anakinra, 100 mg (2 mg/kg) daily, with transient complete resolution of
the episodes. After 1 year on therapy with anakinra he had a new relapse
with fever, skin rash and splenomegaly, pancytopenia (haemoglobin 10,5
g/dL, neutrophils 580/ul and mild thrombocytopenia 123000/ul), mild
elevation of ferritin (600,5 ng/ml), and increased liver enzymes (AST
281 UI/L, ALT 328 UI/L). A quick response to 2 mg/kg/day of prednisolone
was observed. Anakinra was then substituted by canakinumab leading to
sustained remission. The analysis of a whole-exome sequencing (WES)
based custom-designed virtual panel with 93 genes for auto-inflammatory
syndromes, found a novel nonsense heterozygous variant in theNLRP12 gene (c.1952C>A; p.(Ser651*)), inherited from
his father. This variant falls between the NACHT and LRR domains of the
protein, a location that was previously shown to be critical for protein
function (5).
This variant is present in a very low frequency (0,0016%) in genome
aggregation database (GnomAD) and has a CADD Score of 34. A few other
loss-of-function (LoF) variants have already been reported inNLRP12 , associated with FCAS, suggesting its sensitivity to LoF
(6). Studies have suspected that NLRP12 -related conditions have a
paternal origin, with phenotypic variability (6,7). NLRP12variants are associated with autosomal dominant autoinflammatory
disorders with incomplete penetrance (6,7), which is consistent with the
milder phenotype in the father of this case, who only had cold
urticaria, and in which we found the same nonsense heterozygous variant
in the NLRP12 gene.
NLRP12 is a pleiotropic protein, which is activated by microbial
proteins and intracellular components after cell damage. It works as an
immune regulator of the innate immune response, inhibiting both the
canonical and non-canonical nuclear factor-kB (NF-kB) pathway (2,6,8).
LoF variants compromise the regulation of the NF-kB pathway, leading to
an increased and uncontrolled production of the pro-inflammatory
cytokine IL-1ß (6) that can be targeted by interleukin-1 receptor
antagonists (figure 2). Three drugs that target IL-1 have been used to
treat FCAS: anakinra, a short-acting recombinant IL-1 receptor
antagonist; and rilonacept and canakinumab, two long-acting
IL-1-blockers (9). Due to its rarity, the prognosis of FCAS2 is unknown,
however, good results have been reported with prolonged and sustained
remission using IL-1 receptor antagonists (3).
Very interestingly, it has been shown that single allelic variants inNLRP12 were associated with HLH in a group of patients with HLH
but without biallelic mutations in the recognized familial HLH genes
(10). This would support a role for NLRP12 in the pathogenesis of
HLH in our patient.
In conclusion, we describe a novel NLRP12 variant, identified in
an adolescent with HLH and recurrent episodes of cold-induced rash and
fever. This report expands the range of disease causing variants in theNLRP12 gene and further illustrates the complexity of phenotypes
associated with this gene dysfunction.
Key words: familial cold autoinflammatory syndrome,NLRP12 , adolescent, anakinra, canakinumab, autosomal dominant,
incomplete penetrance, case report